Dopaminergic Neuron Therapies
Engineer A9‑like dopaminergic neurons, standardize identity and potency, and translate faster with GMP‑ready reagents.
The Evolving Pathway to Clinical Dopaminergic Neuron Therapy
The progressive loss of A9 midbrain dopamine neurons in Parkinson’s disease (PD) provides a clear target for cell replacement therapy. Early clinical trials with pluripotent stem cell-derived (PSC) dopaminergic progenitors have demonstrated neurological motor function improvements, but full therapeutic translation will require the consistent generation of highly functional cells at scale. R&D Systems reagents and analytical solutions support the development and clinical manufacture of dopaminergic neuron stem cell therapies, from research to clinic.
Customer Success Testimonial
"We are developing autologous iPSC-derived cell therapies to treat neurodegenerative diseases, beginning with Parkinson's disease. Our experience partnering with Bio‑Techne has been very positive. We have been consistently impressed by the performance, quality, and reliability of their GMP‑grade materials. As our program continues to progress toward commercialization, Bio‑Techne has proven to be a responsive and dependable partner."
Natalie Maloney
Scientist I, Process Development
Aspen Neuroscience
Benefits of iPSC-Derived Dopaminergic Neurons
- Supply: Primary human neurons can be difficult to source, whereas stem cells offer a controlled, renewable source of functional neurons that can be produced in larger quantities and standardized more easily.
- Cell Quality: Donor cells can be inconsistent, but tightly controlling differentiation enables the generation of high-quality PSC-derived neurons, including induced PSCs and human embryonic stem cells, capable of more physiologically relevant and consistent dopamine secretion responses.
Translational Challenges Faced by PD Therapy Developers
- Consistency: Small variations in the culture environment can significantly impact neuronal maturation and functionality. R&D Systems reagents minimize lot-to-lot variability and support reproducible late‑stage differentiation.
- Regulatory Compliance: R&D Systems cell culture reagents are tested to be functionally consistent across research- and GMP-grades, facilitating IND submissions with the FDA, and easing your transition to clinical manufacturing.
- Scalability: Scaling cell manufacturing requires consistent raw material inputs and secure supply to maintain performance across manufacture batches and sites. Our flexible cell culture reagents and robust immunoassays are designed to scale with your workflow.
PSC-Derived Dopaminergic Workflow
Developing effective cell therapies for Parkinson’s Disease requires precise control of differentiation, while confirming cell fate and functionality at multiple steps throughout the workflow. R&D Systems portfolio includes well-characterized animal-free recombinant proteins, small molecules, media, supplements, antibodies and ELISA kits to support each of these steps. With consistent high-quality performance, these products help researchers generate reliable results to advance their cell therapy programs with confidence.
Induced Pluripotent Stem Cell (iPSC) Maintenance & Expansion
- ExCellerate™ iPSC Expansion Medium (Animal‑Free, GMP) — consistent growth and viability.
- R&D Systems FGF basic (GMP) — supports pluripotent maintenance with improved handling.
Midbrain Floor‑Plate Induction & Patterning (A9 Fate)
- R&D Systems Small Molecules — CHIR99021 (WNT activation), LDN 193189 (BMP inhibition), Y‑27632 (survival during transitions).
- R&D Systems Proteins — SHH & FGF8 to drive floor‑plate fate; BDNF/GDNF to support DA lineage and survival.
- Cultrex™ Synthetic Hydrogel — tunable mechanics for patterned 2D or 3D midbrain organoids.
Identity, Purity & Potency (Release‑Ready Analytics)
- R&D Systems Antibodies — TH, NURR1, LMX1A/B, FOXA2, PITX3, MAP2, DAT panels for IF/flow/IHC.
- Protein Simple™ Simple Western™ (Jess/Leo) — automated, quantitative protein analysis from minimal material; reproducible reports supporting internal QC and submissions.
Preclinical Functional Evidence
- Simple Plex™ (Ella) Immunoassays — quantify neurotrophic and inflammatory factors with high sensitivity.
- Tocris Toolkit — calcium‑imaging dyes and ion channel modulators to support electrophysiology screening.
Clinical Translation & GMP Advantages With R&D Systems
As you progress toward IND‑enabling studies and manufacturing scale‑up, we provide an integrated foundation of GMP‑ready raw materials, regulatory documentation, and high‑consistency manufacturing that reduces comparability risk and simplifies your CMC pathway.
What You Gain with R&D Systems:
- Seamless RUO to GMP continuity across cytokines, supplements, ECMs, and critical raw materials-minimizing re‑validation and de‑risking transitions into clinical manufacturing.
- GMP‑grade supplements & HSA with secure, traceable supply aligned with CMC expectations and long‑term manufacturing needs.
- Cross‑brand documentation support (COA/COO, traceability statements, qualification data) to ease IND submission timelines.
- A single, unified ecosystem of reagents, ECMs, spatial assays, and automated analytics, all designed to reduce vendor complexity and accelerate treatment of Parkinson’s disease through therapy development.
Which dopaminergic subtype is most relevant for PD cell therapy?
The A9 midbrain dopaminergic neurons projecting to the posterior putamen are key; their loss underpins parkinsonian motor symptoms and is the focus of replacement strategies for this neurodegenerative disease. Learn about iPSC-derived neural models for studying Alzheimer's disease.
What clinical evidence supports dopa neuron therapy?
Phase I/II trials with pluripotent‑derived dopaminergic progenitors report safety and motor improvements with DAT PET evidence of graft survival; autologous iPS cell studies are underway. Both open-label and double-blind, placebo-controlled clinical studies are being used to assess safety, efficacy, and patient outcomes. Investigators and clinician researchers monitor patient baseline measurements, conduct long-term follow-up, and evaluate for serious adverse events, dyskinesias, and symptom improvement. See Stem Cell Reports article on modeling Alzheimer's in human iPSC and the NIH's iPSC Neurodegenerative Disease Initiative (iNDI) for more.
How can I reduce variability in my dopaminergic differentiation runs?
Use defined ECMs (Cultrex™), high‑quality recombinant proteins (R&D Systems), and precisely characterized small molecules (Tocris); then verify phenotype with RNAscope™ and Simple Western™ for reproducible, low‑input analytics.
- Webinar: Best Practices for iPSC Culture and Differentiation
- Webinar: Tools to Optimize Neural and Cardiac Differentiation from iPSCs
- R&D Systems Reagents and Kits
How does R&D Systems simplify the transition from RUO to GMP?
The conversion from RUO to GMP is simplified with ProPak™ GMP cytokines, GMP‑grade media and supplements, single‑use formats for closed systems, and documentation support across brands to facilitate regulatory review for clinical studies.
How are stem-cell based therapies being used to treat Parkinson’s patients?
Neuroscience researchers are studying dopaminergic cells, dopamine-producing neurons, and progenitor cells to find ways to restore dopamine production in the substantia nigra and striatum, helping address symptoms associated with the progression of movement disorders like Parkinson’s. These approaches have the potential to complement traditional treatments of levodopa, dopamine agonist therapy, and deep brain stimulation, while improving long-term quality of life.
What is involved in cell transplantation and implantation procedures for Parkinson’s research?
Cell transplantation research, including both allogeneic and autologous approaches, relies on specialized neurosurgery procedures and precise implantation techniques to deliver transplanted cells to targeted areas of the brain. Researchers evaluate the role of immunosuppression, monitor tolerability, and study how transplanted cells survive and function within the brain following stem cell treatments.